GM Wheat Fails in the Field

A field trial of wheat genetically engineered to resist aphids fails to measure up to lab tests.

| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

WIKIMEDIA

In an effort to cut back on the need for pesticides, many research groups have developed genetically modified (GM) wheat that can fight pathogens and resist pests. Besides incidental appearances of Monsanto’s Round-up Ready wheat, just one variety of GM wheat has made it out of the lab and into the field for testing. But according to a study published in Scientific Reports yesterday (June 25), those field trials have failed.

Researchers at Rothamsted Research in Harpenden, U.K., designed the study, which took place over the course of several months in 2012 and 2013, to test the resistance of wheat programmed to make a pheromone that repels aphids, insects that feed on and transmit viruses to plants. The pheromone, called (E)-β-farnesene (Eβf) also attracts some ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Keywords

Meet the Author

  • Amanda B. Keener

    This person does not yet have a bio.
Share
TS Digest January 2025
January 2025, Issue 1

Why Do Some People Get Drunk Faster Than Others?

Genetics and tolerance shake up how alcohol affects each person, creating a unique cocktail of experiences.

View this Issue
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo
New Frontiers in Vaccine Development

New Frontiers in Vaccine Development

Sino
New Approaches for Decoding Cancer at the Single-Cell Level

New Approaches for Decoding Cancer at the Single-Cell Level

Biotium logo
Learn How 3D Cell Cultures Advance Tissue Regeneration

Organoids as a Tool for Tissue Regeneration Research 

Acro 

Products

Artificial Inc. Logo

Artificial Inc. proof-of-concept data demonstrates platform capabilities with NVIDIA’s BioNeMo

Sapient Logo

Sapient Partners with Alamar Biosciences to Extend Targeted Proteomics Services Using NULISA™ Assays for Cytokines, Chemokines, and Inflammatory Mediators

Bio-Rad Logo

Bio-Rad Extends Range of Vericheck ddPCR Empty-Full Capsid Kits to Optimize AAV Vector Characterization

Scientist holding a blood sample tube labeled Mycoplasma test in front of many other tubes containing patient samples

Accelerating Mycoplasma Testing for Targeted Therapy Development